The RTS,S vaccine candidate for malaria

  title={The RTS,S vaccine candidate for malaria},
  author={Jason A. Regules and James F. Cummings and Christian Ockenhouse},
  journal={Expert Review of Vaccines},
  pages={589 - 599}
Malaria continues to be a worldwide leading cause of morbidity and mortality, and the development of an effective malaria vaccine remains a research imperative. Of the multiple approaches that have been pursued, the RTS,S/AS01 vaccine candidate represents the most developed and clinically validated malaria vaccine formulation. Throughout its development, increasingly more effective adjuvants have been key in improving the potency of the vaccine. RTS,S-based vaccine formulations have been… 

Immune mechanisms in malaria: new insights in vaccine development

It is argued that rational design of more effective malaria vaccines will be accelerated by a better understanding of the immune effector mechanisms involved in parasite regulation, control and elimination.

Implementation of RTS,S/AS01 Malaria Vaccine--The Need for Further Evidence.

RTS,S/AS01, a recombinant vaccine against the pre-erythrocytic stage of the parasite in which regions of P. falciparum circumsporozoite protein are fused to hepatitis B surface antigen is presented.

Plasmodium falciparum Malaria Vaccines and Vaccine Adjuvants

An overview of the current knowledge of anti-malarial immunity against P. falciparum and different options of vaccine candidates in development is provided, with a special emphasis on the mechanism of action of clinically used vaccine adjuvants.

Challenges and responses in human vaccine development.

Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine

It is demonstrated that in BALB/c mice R21 is immunogenic at very low doses and when administered with the adjuvants Abisco-100 and Matrix-M it elicits sterile protection against transgenic sporozoite challenge.

The malaria vaccine--status quo 2013.

  • D. Heppner
  • Medicine
    Travel medicine and infectious disease
  • 2013



Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1–4 in Mozambique

The RTS,S/AS02A candidate malaria vaccine has been shown to be safe and immunogenic in previous studies in adults and staggered dose‐escalation studies in children in The Gambia, and genetic features and the intensity of malaria transmission may modify the safety and immune response.

Adjuvants for malaria vaccines

The current state of adjuvant research and development as it pertains to effective malaria vaccines is outlined.

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age.

RTS,S/AS01E shows promise as a candidate malaria vaccine as compared with rabies vaccine in children in Kilifi, Kenya, and Korogwe, Tanzania, a target population for vaccine licensure.

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants.

The use of the RTS,S/AS02D vaccine in infants had a promising safety profile, did not interfere with the immunologic responses to coadministered EPI antigens, and reduced the incidence of malaria infection.

Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization.

RTS,S/AS01(E) integrated in the EPI showed a favorable safety and immunogenicity evaluation, and rates of response to polio 3 antigens were comparable between groups.

A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia.

It is concluded that the RTS,S/SBAS2 vaccine induces no significant toxicity in this semi-immune population and produces significant increases in antibody titers to CSP.

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.

A recombinant vaccine based on fusion of the circumsporozoite protein and HBsAg plus a potent adjuvant can protect against experimental challenge with P. falciparum malaria.

Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western Kenya.

RTS,S/AS02A is safe and similarly immunogenic in malaria-exposed African adults of different ethnicity in different transmission settings, and these safety and immunogenicity data from adults in hyperendemic Kenya are comparable to data reported earlier from two trials in west African adults in hypo-endemic and meso- endemic areas of The Gambia.

A Randomized Trial Assessing the Safety and Immunogenicity of AS01 and AS02 Adjuvanted RTS,S Malaria Vaccine Candidates in Children in Gabon

RTS,S/AS01E proved similarly as well tolerated and immunogenic as RTS, S/AS02D, completing an essential step in the age de-escalation process within the R TS,S clinical development plan.